Two Chinese COVID-19 medicines receive emergency approval
BEIJING -- The National Medical Products Administration (NMPA) has given emergency approval to the registration application of two COVID-19 medicines, BRII-196 and BRII-198.
This is China's first approved COVID-19 virus-neutralizing antibody combination therapy with independent intellectual property rights.
The two medicines are used in combination to treat adult and adolescent patients with mild and moderate symptoms and with severe risk factors for progression, according to the NMPA. Specifically, the medicines are conditionally approved for adolescents ranging from 12 to 17 years of age with a body weight greater than 40 kg.
Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences have jointly developed the cocktail therapy of monoclonal antibodies BRII-196 and BRII-198, which are derived from antibodies isolated from people who have recovered from COVID-19.
- Draft law on national fire and rescue personnel submitted for second reading
- Fireflies light up Yunnan's night sky
- Afforestation hero's US friend to return to China at the end of August
- Over 9,100 residents evacuated as rainstorms hit SW China
- China has 22 recognized WMO centennial observing stations
- China's draft financial law submitted for first reading
